Copyright © Inderes 2011 - present. All rights reserved.

Oriola

1.16 EUR

+1.58 %

7,729 following

ORIOLA

NASDAQ Helsinki

Medical Equipment & Services

Health Care

+1.58 %
+3.95 %
+8.43 %
+7.22 %
+30.11 %
+23.06 %
-36.16 %
-38.73 %
-37.04 %

Oriola is a pharmaceutical group with a particular focus on the distribution of pharmaceuticals to other players in the industry. The company offers services to pharmacies and other pharmaceutical companies, which includes, for example, negotiations with suppliers and distribution of products. The largest operations are in the Nordic and Baltic regions. The headquarters are located in Espoo.

Read more
Market cap
214.61M EUR
Turnover
51.49K EUR
P/E (adj.) (25e)
27.44
EV/EBIT (adj.) (25e)
4.68
P/B (25e)
1.89
EV/S (25e)
0.06
Dividend yield-% (25e)
6.04 %
Coverage
Recommendation
Accumulate
Target price
1.25 EUR
Updated
31.10.2025
Disclaimer
Rauli Juva
Rauli Juva

Analyst

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types
Third party research

Oriola: Earnings turning positive - Evli

Oriola posted good Q3 results, with a key positive the faster recovery than we had expected recovery of profitability in the Wholesale segment. With good development across the board, earnings also turned positive. We raise our target price to EUR 1....

Oriola
Third party research

Oriola: Good development across the board - Evli

Oriola posted good figures in Q3. Net sales growth was nearly in the double-digits, while the adj. EBITDA of EUR 9.6m exceeded our EUR 9.1m expectations. Profitability was aided by faster than anticipated profitability recovery of the Wholesale-segment...

Oriola

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research

Oriola: Growth in place, profitability next - Evli

Oriola saw solid growth in Q2, and we anticipate a continued good growth pace in Q3. We expect the weaker profitability in the Wholesale-segment to improve gradually during the second half of the year, enabling y/y group level improvement.

Oriola
Third party research

Oriola: Profitability drivers in place - Evli

Solid growth, profitability on previous year levels Oriola posted solid growth figures in Q2, while profitability development remained modest. Net sales growth exceeded our expectations, up 12% y/y to EUR 493.9m (EUR 473.7m/496.7m Evli/cons.). The adj...

Oriola
Third party research

Oriola: Eyeing gradual improvements - Evli

Oriola More cautious stance on Wholesale profitability Oriola reports its Q2 results on July 18th. Performance in Q1 was fairly good but mixed. While the Distribution-segment continued to show good growth and volume driven profitability improvements ...

Oriola
Forum discussions
Familiar Oriola. The further down the lines you read, the more minus signs start appearing, and then you’d need some accounting degree to understand if the result is good or bad. I tried to go through the adjustment items, but even there, inconsistencies immediately caught a layman...
10/30/2025, 6:55 AM
by Cotr
12
This is what Oriola offered: https://www.kauppalehti.fi/porssitiedotteet/a/a0ad029c-d6d0-56b8-8e03-a8521a841519
10/30/2025, 6:35 AM
by NukkeNukuttaja
10
Rauli has had time to give his comments on Oriola’s Q3 results. Oriola’s result improved slightly more than we expected, both in its own operations and in the joint venture Kronans. The full-year guidance for improving adjusted operating profit was reiterated as expected, and after...
10/30/2025, 8:46 AM
by Sijoittaja-alokas
6
Rauli has prepared a new company report on Oriola after the Q3 results were
10/31/2025, 5:43 AM
by Sijoittaja-alokas
5
Rauli already had the chance to interview Oriola’s CEO, Katarina Gabrielson. https://www.inderes.fi/videos/oriola-q325-positiivista-kehitysta-eng Topics: 00:00 Introduction 00:11 Q3 development 00:36 Distribution segment brought profit improvement 01:22 Swedish market is growing ...
10/30/2025, 12:50 PM
by Sijoittaja-alokas
4
We’ll probably get a decision from the government on the removal of pharmacy regulation quite soon. As for whether Kesko is the top buyer candidate, everyone can consider that for themselves. Definitely not the worst guess.
10/29/2025, 7:54 AM
by Harmiton
4
Two share classes have been one obstacle to the acquisition. Now it has been removed. Oriola’s dismal performance has been another obstacle. The trend is now turning. The pharmacy situation has been resolved, although the joint venture’s success has been dismal so far. Soon the time...
10/28/2025, 10:04 AM
by Kryptoniitti
3
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.